|
US8846935B2
(en)
|
2010-05-07 |
2014-09-30 |
Glaxosmithkline Llc |
Indazoles
|
|
US20130102477A1
(en)
|
2010-06-23 |
2013-04-25 |
Ryan D. Morin |
Biomarkers for non-hodgkin lymphomas and uses thereof
|
|
BR112013005806B1
(pt)
|
2010-09-10 |
2022-05-10 |
Epizyme, Inc |
Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
|
|
US9175331B2
(en)
|
2010-09-10 |
2015-11-03 |
Epizyme, Inc. |
Inhibitors of human EZH2, and methods of use thereof
|
|
ES2607064T3
(es)
*
|
2010-12-01 |
2017-03-29 |
Glaxosmithkline Llc |
Indoles
|
|
ES2951688T3
(es)
|
2011-02-28 |
2023-10-24 |
Epizyme Inc |
Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos
|
|
AU2013203641B2
(en)
*
|
2011-04-13 |
2014-08-21 |
Epizyme, Inc. |
Aryl-or heteroaryl-substituted benzene compounds
|
|
JO3363B1
(ar)
|
2011-04-13 |
2019-03-13 |
Epizyme Inc |
مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
|
|
TWI598336B
(zh)
|
2011-04-13 |
2017-09-11 |
雅酶股份有限公司 |
經取代之苯化合物
|
|
CA2850570A1
(en)
|
2011-09-30 |
2013-04-04 |
Glaxosmithkline Llc |
Methods of treating cancer
|
|
BR112014010803A2
(pt)
*
|
2011-11-04 |
2017-04-25 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
método de tratamento
|
|
EP2780014A4
(en)
*
|
2011-11-18 |
2015-07-01 |
Constellation Pharmaceuticals Inc |
MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
|
|
EP2780013A4
(en)
|
2011-11-18 |
2015-07-01 |
Constellation Pharmaceuticals Inc |
MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
|
|
WO2013096744A1
(en)
|
2011-12-21 |
2013-06-27 |
Novira Therapeutics, Inc. |
Hepatitis b antiviral agents
|
|
NZ628762A
(en)
|
2012-02-10 |
2016-07-29 |
Constellation Pharmaceuticals Inc |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
EP3536314A1
(en)
|
2012-03-12 |
2019-09-11 |
Epizyme, Inc. |
Inhibitors of human ezh2, and methods of use thereof
|
|
EP2828250B1
(en)
|
2012-03-19 |
2021-03-10 |
Imperial College Innovations Limited |
Quinazoline compounds and their use in therapy
|
|
PT3184523T
(pt)
*
|
2012-04-13 |
2019-09-26 |
Eisai R&D Man Co Ltd |
Bromidrato de n-((4,6-dimetil-2-oxo-l,2-di-hidropiridin- 3-il)metil)-5-(etil(tetra-hidro-2h-piran-4-il)amino)-4- metil-4¿-(morfolinometil)-[l,1¿-bofenil]-3-carboxamida para utilização no tratamento de uma doença proliferativa celular do sistema hematológico
|
|
WO2013173441A2
(en)
*
|
2012-05-16 |
2013-11-21 |
Glaxosmithkline Llc |
Enhancer of zeste homolog 2 inhibitors
|
|
AU2013274036B2
(en)
|
2012-06-14 |
2017-08-17 |
Dana-Farber Cancer Institute, Inc. |
Genome-wide method of assessing interactions between chemical entities and their target molecules
|
|
EA038942B1
(ru)
|
2012-08-28 |
2021-11-12 |
Янссен Сайенсиз Айрлэнд Юси |
Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
|
|
JP6254169B2
(ja)
*
|
2012-09-28 |
2017-12-27 |
ファイザー・インク |
ベンズアミドおよびヘテロベンズアミド化合物
|
|
KR20230156450A
(ko)
|
2012-10-15 |
2023-11-14 |
에피자임, 인코포레이티드 |
암을 치료하는 방법
|
|
MX2015004721A
(es)
*
|
2012-10-15 |
2016-01-25 |
Epizyme Inc |
Compuestos de benceno sustituidos.
|
|
EP2931707A4
(en)
*
|
2012-12-13 |
2016-07-20 |
Glaxosmithkline Llc |
AMPLIFIER OF ZEST HOMOLOG 2 INHIBITORS
|
|
EP2934531A4
(en)
*
|
2012-12-19 |
2016-06-15 |
Glaxosmithkline Llc |
COMBINATION
|
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
|
CA2894222A1
(en)
|
2012-12-21 |
2014-06-26 |
Epizyme, Inc. |
1,4-pyridone bicyclic heteroaryl compounds
|
|
SI2953941T1
(sl)
*
|
2013-02-11 |
2017-08-31 |
Constellation Pharmaceuticals, Inc. |
Modulatorji metil-modificirajočih encimov, sestavki in uporabe le-teh
|
|
HUE034820T2
(en)
|
2013-02-28 |
2018-02-28 |
Janssen Sciences Ireland Uc |
Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
|
|
US8993771B2
(en)
|
2013-03-12 |
2015-03-31 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
|
EP3363434A1
(en)
|
2013-03-14 |
2018-08-22 |
Epizyme Inc |
Arginine methyltransferase inhibitors and uses thereof
|
|
WO2014153172A1
(en)
|
2013-03-14 |
2014-09-25 |
Epizyme, Inc. |
Pyrazole derivatives as prmt1 inhibitors and uses thereof
|
|
CA2903264A1
(en)
|
2013-03-14 |
2014-11-06 |
Epizyme, Inc. |
Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
|
|
PL2970132T3
(pl)
|
2013-03-14 |
2021-04-06 |
Epizyme, Inc. |
Inhibitory metylotransferazy argininy i ich zastosowania
|
|
KR20150127216A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
암의 치료 및 암 약물 내성의 예방 방법
|
|
US9120757B2
(en)
|
2013-03-14 |
2015-09-01 |
Epizyme, Inc. |
Arginine methyltransferase inhibitors and uses thereof
|
|
US9023883B2
(en)
|
2013-03-14 |
2015-05-05 |
Epizyme, Inc. |
PRMT1 inhibitors and uses thereof
|
|
EP2970134B1
(en)
|
2013-03-14 |
2018-02-28 |
Epizyme, Inc. |
Pyrazole derivatives as prmt1 inhibitors and uses thereof
|
|
US9765035B2
(en)
|
2013-03-14 |
2017-09-19 |
Epizyme, Inc. |
Arginine methyltransferase inhibitors and uses thereof
|
|
EP2970136A1
(en)
|
2013-03-14 |
2016-01-20 |
Epizyme, Inc. |
Arginine methyl transferase inhibtors and uses thereof
|
|
US9045455B2
(en)
|
2013-03-14 |
2015-06-02 |
Epizyme, Inc. |
Arginine methyltransferase inhibitors and uses thereof
|
|
WO2014151142A1
(en)
*
|
2013-03-15 |
2014-09-25 |
Constellation Pharmaceuticals, Inc. |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
WO2014155301A1
(en)
*
|
2013-03-26 |
2014-10-02 |
Piramal Enterprises Limited |
Substituted bicyclic compounds as inhibitors of ezh2
|
|
EA027068B1
(ru)
|
2013-04-03 |
2017-06-30 |
Янссен Сайенсиз Айрлэнд Юси |
Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
|
|
EP2991980B1
(en)
*
|
2013-04-30 |
2019-01-02 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Enhancer of zeste homolog 2 inhibitors
|
|
TWI651300B
(zh)
|
2013-05-17 |
2019-02-21 |
健生科學愛爾蘭無限公司 |
胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
|
|
EA035500B1
(ru)
|
2013-05-17 |
2020-06-25 |
Янссен Сайенсиз Айрлэнд Юси |
Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b
|
|
BR112015030515A2
(pt)
*
|
2013-06-06 |
2017-07-25 |
Glaxosmithkline Ip No 2 Ltd |
intensificadores de inibidores de homólogo 2 de zeste
|
|
KR20160030221A
(ko)
|
2013-07-10 |
2016-03-16 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
제스트 인핸서 상동체 2 억제제
|
|
DK3024819T3
(en)
|
2013-07-25 |
2018-06-06 |
Janssen Sciences Ireland Uc |
GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
|
|
EP3033334A1
(en)
*
|
2013-08-15 |
2016-06-22 |
Constellation Pharmaceuticals, Inc. |
Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
|
|
MA38949A1
(fr)
|
2013-10-16 |
2017-07-31 |
Eisai R&D Man Co Ltd |
Forme saline d'hydrochlorure pour inhibition d'ezh2
|
|
KR102290189B1
(ko)
|
2013-10-23 |
2021-08-17 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
|
|
WO2015077194A1
(en)
*
|
2013-11-22 |
2015-05-28 |
Bristol-Myers Squibb Company |
Inhibitors of lysine methyl transferase
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
JP6553059B2
(ja)
|
2014-02-05 |
2019-07-31 |
ノヴィラ・セラピューティクス・インコーポレイテッド |
Ｈｂｖ感染の治療のための併用療法
|
|
WO2015118057A1
(en)
|
2014-02-06 |
2015-08-13 |
Janssen Sciences Ireland Uc |
Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
|
US20160340674A1
(en)
*
|
2014-02-10 |
2016-11-24 |
University Of Rochester |
Compositions and Methods to Inhibit EZH2 for the Treatment of Cardiovascular Diseases
|
|
WO2015128837A1
(en)
|
2014-02-26 |
2015-09-03 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Methods of treating cancer patients responding to ezh2 inhibitor gsk126
|
|
EP3119390A4
(en)
*
|
2014-03-21 |
2017-09-20 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Methods of treating cancer
|
|
CN105037360B
(zh)
*
|
2014-04-28 |
2016-08-17 |
四川大学 |
吡啶酮衍生物及其制备方法和用途
|
|
CN105017221B
(zh)
*
|
2014-04-30 |
2019-05-28 |
中国医学科学院药物研究所 |
苯并咪唑衍生物及其制法和药物组合物与用途
|
|
EP3157915B1
(en)
|
2014-06-17 |
2019-02-27 |
Pfizer Inc |
Substituted dihydroisoquinolinone compounds
|
|
WO2015200650A1
(en)
*
|
2014-06-25 |
2015-12-30 |
Epizyme, Inc. |
Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
|
|
CN107148419A
(zh)
*
|
2014-10-28 |
2017-09-08 |
葛兰素史密斯克莱知识产权（第2 号）有限公司 |
Zeste增强子同源物2抑制剂
|
|
EP3885343A1
(en)
|
2014-11-06 |
2021-09-29 |
Dana-Farber Cancer Institute, Inc. |
Indole compounds as ezh2 inhibitors and uses thereof
|
|
AR102767A1
(es)
|
2014-12-05 |
2017-03-22 |
Lilly Co Eli |
Inhibidores de ezh2
|
|
WO2016102493A1
(en)
*
|
2014-12-22 |
2016-06-30 |
Bayer Pharma Aktiengesellschaft |
Imidazopyridine ezh2 inhibitors
|
|
WO2016101956A2
(en)
|
2014-12-23 |
2016-06-30 |
University Of Copenhagen |
Treatment of cancer by inhibiting ezh2 activity
|
|
CA2969090C
(en)
*
|
2014-12-23 |
2023-05-02 |
Novartis Ag |
Triazolopyrimidine compounds and uses thereof
|
|
EP3271019A1
(en)
|
2015-03-19 |
2018-01-24 |
Novira Therapeutics Inc. |
Azocane and azonane derivatives and methods of treating hepatitis b infections
|
|
US10961532B2
(en)
|
2015-04-07 |
2021-03-30 |
The General Hospital Corporation |
Methods for reactivating genes on the inactive X chromosome
|
|
AU2016275051A1
(en)
*
|
2015-06-10 |
2017-12-07 |
Epizyme, Inc. |
EZH2 inhibitors for treating lymphoma
|
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
WO2017035234A1
(en)
|
2015-08-24 |
2017-03-02 |
Epizyme, Inc. |
Method for treating cancer
|
|
TW201718598A
(zh)
|
2015-08-27 |
2017-06-01 |
美國禮來大藥廠 |
Ｅｚｈ２抑制劑
|
|
US10577350B2
(en)
|
2015-08-28 |
2020-03-03 |
Constellation Pharmaceuticals, Inc. |
Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
|
|
HK1259410A1
(zh)
|
2015-09-29 |
2019-11-29 |
诺维拉治疗公司 |
乙型肝炎抗病毒剂的晶体形式
|
|
AU2016333982A1
(en)
|
2015-10-06 |
2018-04-26 |
Epizyme, Inc. |
Method of treating medulloblastoma with an EZH2 inhibitor
|
|
US20180321256A1
(en)
|
2015-11-05 |
2018-11-08 |
Epizyme, Inc. |
Flow cytometry for monitoring histone h3 methylation status
|
|
RS59763B1
(sr)
*
|
2015-11-19 |
2020-02-28 |
Jiangsu Hengrui Medicine Co |
Derivati benzofurana, postupci njihove pripreme i njihova upotreba u medicini
|
|
EP3407978A4
(en)
|
2016-01-29 |
2020-01-15 |
Epizyme Inc |
POLYTHERAPY FOR THE TREATMENT OF CANCER
|
|
WO2017139455A1
(en)
|
2016-02-10 |
2017-08-17 |
Wake Forest University Health Sciences |
Model system of liver fibrosis and method of making and using the same
|
|
ES3057783T3
(en)
|
2016-03-15 |
2026-03-04 |
Oryzon Genomics Sa |
Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
|
|
SG10202011827YA
(en)
|
2016-04-15 |
2021-01-28 |
Novira Therapeutics Inc |
Combinations and methods comprising a capsid assembly inhibitor
|
|
AU2017252460B2
(en)
|
2016-04-22 |
2021-11-18 |
Dana-Farber Cancer Institute, Inc. |
EZH2 inhibitors and uses thereof
|
|
CN105777718B
(zh)
*
|
2016-04-27 |
2019-03-19 |
上海应用技术学院 |
潜在ezh2小分子抑制剂及其合成方法
|
|
US10987353B2
(en)
|
2016-05-04 |
2021-04-27 |
The Wistar Institute Of Anatomy And Biology |
Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs
|
|
WO2017218953A1
(en)
|
2016-06-17 |
2017-12-21 |
Epizyme, Inc. |
Ezh2 inhibitors for treating cancer
|
|
WO2017221092A1
(en)
*
|
2016-06-20 |
2017-12-28 |
Novartis Ag |
Triazolopyridine compounds and uses thereof
|
|
CN107573327B
(zh)
*
|
2016-07-05 |
2020-03-31 |
四川大学 |
吲唑-甲酰胺-吡啶酮衍生物及其制备方法和用途
|
|
CN107573336B
(zh)
*
|
2016-07-05 |
2021-01-19 |
四川大学 |
苯并杂环-甲酰胺-吡啶酮衍生物及其制备方法和用途
|
|
US10457640B2
(en)
|
2016-10-19 |
2019-10-29 |
Constellation Pharmaceuticals, Inc. |
Synthesis of inhibitors of EZH2
|
|
US10793549B2
(en)
|
2016-11-11 |
2020-10-06 |
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. |
Sulfuryl-substituted benzoheterocyclic derivative, preparation method and medical use thereof
|
|
WO2018086589A1
(zh)
*
|
2016-11-11 |
2018-05-17 |
上海海雁医药科技有限公司 |
1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途
|
|
JP7208898B2
(ja)
|
2016-12-02 |
2023-01-19 |
エピザイム，インコーポレイティド |
癌を処置するための併用療法
|
|
JP7125353B2
(ja)
*
|
2017-01-19 |
2022-08-24 |
第一三共株式会社 |
Ｈｔｌｖ－１関連脊髄症を治療することに用いるための医薬組成物
|
|
US10266542B2
(en)
|
2017-03-15 |
2019-04-23 |
Mirati Therapeutics, Inc. |
EZH2 inhibitors
|
|
WO2018183885A1
(en)
|
2017-03-31 |
2018-10-04 |
Epizyme, Inc. |
Combination therapy for treating cancer
|
|
WO2018231973A1
(en)
|
2017-06-13 |
2018-12-20 |
Epizyme, Inc. |
Inhibitors of ezh2 and methods of use thereof
|
|
KR20200088386A
(ko)
|
2017-11-14 |
2020-07-22 |
화이자 인코포레이티드 |
Ezh2 억제제 병용 요법
|
|
DK3746446T3
(da)
|
2018-01-31 |
2022-06-27 |
Mirati Therapeutics Inc |
PRC2-inhibitorer
|
|
CN110229151B
(zh)
*
|
2018-03-06 |
2021-09-10 |
上海海和药物研究开发股份有限公司 |
吲嗪类化合物、其制备方法及用途
|
|
CA3090125A1
(en)
|
2018-03-14 |
2019-09-19 |
Janssen Sciences Ireland Unlimited Company |
Capsid assembly modulator dosing regimen
|
|
CA3104209A1
(en)
|
2018-07-09 |
2020-01-16 |
Fondation Asile Des Aveugles |
Inhibition of prc2 subunits to treat eye disorders
|
|
CN111683936B
(zh)
|
2018-07-27 |
2021-08-20 |
苏州信诺维医药科技股份有限公司 |
多取代苯环化合物、制备方法及其用途
|
|
MX2021010145A
(es)
|
2019-02-22 |
2021-09-14 |
Janssen Sciences Ireland Unlimited Co |
Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
|
|
CN113773304B
(zh)
*
|
2019-02-25 |
2023-03-10 |
江苏豪森药业集团有限公司 |
抗耐药抗肿瘤egfr抑制剂的制备方法
|
|
US12421228B2
(en)
|
2019-04-22 |
2025-09-23 |
Mirati Therapeutics, Inc. |
Naphthyridine derivatives as PRC2 inhibitors
|
|
MA55879A
(fr)
|
2019-05-06 |
2022-03-16 |
Janssen Sciences Ireland Unlimited Co |
Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
|
|
US12252493B2
(en)
|
2019-06-05 |
2025-03-18 |
Mirati Therapeutics, Inc. |
Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer
|
|
WO2021016414A1
(en)
|
2019-07-24 |
2021-01-28 |
Constellation Pharmaceuticals, Inc. |
Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
|
|
JP2022545467A
(ja)
|
2019-08-22 |
2022-10-27 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法
|
|
US12006232B2
(en)
|
2020-06-09 |
2024-06-11 |
Rapid Water Technology LLC |
Water processing apparatus
|
|
CN117222634A
(zh)
*
|
2020-12-16 |
2023-12-12 |
艾福姆德尤股份有限公司 |
用于治疗与sting活性有关的疾病的化合物和组合物
|
|
CN113307765A
(zh)
*
|
2021-05-24 |
2021-08-27 |
上海泰坦科技股份有限公司 |
吡啶甲胺类化合物及其制备方法
|
|
WO2023025856A1
(en)
|
2021-08-25 |
2023-03-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of ezh2 inhibitors for the treatment of aortic valve stenosis
|
|
WO2023111810A1
(en)
|
2021-12-14 |
2023-06-22 |
Pfizer Inc. |
Combination therapies and uses for treating cancer
|
|
TW202400140A
(zh)
|
2022-04-27 |
2024-01-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合
|
|
CN117088810A
(zh)
*
|
2023-06-27 |
2023-11-21 |
海南医学院 |
3-氰基吡啶酮化合物的串联合成方法
|
|
CN117362277B
(zh)
*
|
2023-10-13 |
2025-02-11 |
沈阳药科大学 |
含咪唑啉酮结构的苯甲酰胺类化合物及其制备方法和应用
|
|
CN118745144A
(zh)
*
|
2024-06-21 |
2024-10-08 |
辽宁大学 |
新型ezh2抑制剂化合物及其制备方法和应用
|